TocilizumabV1, France, Analysis, indexHead, Teeft.i

Index : Teeft.i

Les termes de plus forte occurence

87	Rheumatoid arthritis
74	Rheumatoid
57	Arthritis
54	Rheumatology
44	Disease activity
38	Baseline
34	Tocilizumab
34	Roche
32	Remission
31	Rheum
26	Rituximab
21	Receptor
19	Inadequate response
19	Arthritis rheum
18	Disease duration
17	Rheumatoid arthritis patients
17	Methotrexate
16	Cytokine
16	Adverse events
15	Rheumatol
15	Internal medicine
15	Eular
14	Speakers bureau
14	Clinical trials
14	Biological agents
13	Pfizer
13	Abatacept
12	Monotherapy
12	Disease activity score
11	Tumour necrosis factor
11	Placebo
11	Erythrocyte sedimentation rate
11	American college
11	Abbott
10	Humans
10	Clinical response
10	Clinical practice
10	Clin
10	Biologic
10	Antirheumatic drugs
9	Tnfi
9	Sdai
9	Randomized
9	Randomised
9	Median
9	Epidemiological research
9	Dmards
9	Combination therapy
9	Clinical immunology
9	Biologics
8	Systematic review
8	Squibb
8	Rheumatoid factor
8	Radiographic
8	Primary endpoint
8	Juvenile idiopathic arthritis
8	Eular response
8	Etanercept
8	Cohort
8	Baseline characteristics
8	Ankylosing spondylitis
8	Active disease
7	Treatment groups
7	Systemic
7	Synovial
7	Serious infections
7	Rheumatic diseases
7	Response rates
7	Pathway
7	Novartis
7	Monoclonal antibody
7	Middle Aged
7	Merck
7	Joint damage
7	Infusion
7	Immune
7	Idiopathic
7	Idiopathic arthritis
7	Healthy controls
7	Female
7	Cdai
7	Acpa
6	Tregs
6	Tocilizumab therapy
6	Systemic lupus erythematosus
6	Systematic literature review
6	Steroid
6	Responder
6	Progression
6	Phenotype
6	Pharma
6	Peripheral blood
6	Mrna
6	Immunol
6	Healthy subjects
6	Glucocorticoid
6	Genentech
6	Expert opinion
6	Epidemiological
6	Dmard
6	Control group
6	Clinical trial
6	Clinical remission
6	Adult
6	Adalimumab
5	Wyeth
5	Univ
5	Ultrasound
5	Tumour
5	Treg
5	Structural damage
5	Smolen
5	Severe infections
5	Russian federation
5	Roche products
5	Remission rates
5	Remission criteria
5	Receptor inhibition
5	Psoriatic arthritis
5	Physical function
5	Orthopaedic surgery
5	Nagoya
5	Monocyte
5	Male
5	Lupus
5	Joint counts
5	Insulin resistance
5	Inflammation
5	Immune response
5	Gure
5	French society
5	European league
5	Eular recommendations
5	Corticosteroid
5	Cardiovascular
5	Biological agent
4	Treg cells
4	Treatment Outcome
4	Task force
4	Systemic sclerosis
4	Synovitis
4	Syndrome
4	Statistical analysis
4	States background
4	Sanofi aventis
4	Safety data
4	Risk factors
4	Rheumatology unit
4	Rheumatologist
4	Radiographic progression
4	Pathogenesis
4	Online
4	Online supplement
4	Novartis pharmaceuticals corporation
4	Neutrophil
4	Necrosis
4	Methotrexate therapy
4	Medical science
4	Lipid
4	Lesion
4	Inhibitor
4	Immunogenicity
4	Hospital universitario
4	Global assessment
4	Gene expression
4	Flow cytometry
4	Expression levels
4	Espoir cohort
4	Discontinuation
4	Consulting fees
4	Chugai
4	Biological antirheumatic drugs
4	Biologic therapy
4	Biologic agents
4	Arthralgia
4	Antirheumatic
4	Antibody response
4	Allele
4	Aletaha
4	Action study
4	Abbott laboratories
3	Work productivity
3	Washout period
3	Upper limit
3	University hospital
3	Univ medicine
3	Treatment target
3	Treatment strategies
3	Treatment response
3	Treatment arms
3	Transcriptomic analysis
3	Tocilizumab monotherapy
3	Time point
3	Systemic manifestations
3	Synoviocytes
3	Synovial tissue
3	Spondylitis
3	Smart trial
3	Significant differences
3	Significant difference
3	Siena
3	Side effects
3	Shareholder
3	Severity of Illness Index
3	Serum levels
3	Serum level
3	Serious reactions
3	Rouen
3	Rouen university hospital inserm
3	Roche chuga
3	Rituximab registry
3	Research support
3	Research institute
3	Research grants
3	Research agenda
3	Regional hospital
3	Receptor antagonist
3	Real life
3	Reactive protein
3	Public health
3	Psoriatic
3	Psoriasis
3	Panepistimio kritis
3	Paediatric
3	Paediatric rheumatology
3	Other hand
3	Ospedale
3	Necrosis factor therapy
3	Mutation
3	Multivariate analysis
3	Mrna expression
3	More patients
3	Montpellier
3	Monoclonal antibodies
3	Methotrexate monotherapy
3	Merck pharma gmbh
3	Mcmaster univ
3	Macrophage
3	Lymphocyte
3	Ligand
3	John wiley sons
3	Japan background
3	Intracellular
3	Internistische schwerpunktpraxis
3	Inserm
3	Infliximab
3	Immunosuppressive
3	Immunosuppressive drugs
3	Imaging
3	Hospital barmherzige brueder
3	Horizon pharma
3	Hopital
3	Hiroshima clinic
3	Hepatitis
3	Heijde
3	Health assessment index
3	Growth factor
3	Grant support
3	Good outcome
3	Genotype
3	Functional capacity
3	Freiburg
3	Familial mediterranean fever
3	Ewrr
3	Ewrr abstracts
3	Erythematosus
3	Endpoint
3	Disease onset
3	Disclosure
3	Dendritic
3	Dendritic cells
3	Daily practice
3	Czech republic
3	Cytometry
3	Clinical disease activity index
3	Clin rheumatol
3	Chemokine motif
3	Centre
3	Centocor
3	Cell depletion
3	Canakinumab
3	Breeman research institute
3	Biol
3	Assay
3	Articular
3	Arthritis development
3	Aosd
3	Antibodies, Monoclonal, Humanized
3	Ankylosing
3	Anakinra
3	Amgen
3	Aged
3	Adverse event
3	Adult patients
3	Abbott japan
3	Abbott immunology pharmaceuticals
2	Zoster
2	Viral
2	Vasculitis
2	Vaccine
2	Vaccination
2	Utrecht
2	Usual care
2	Universit
2	Univariate analysis
2	Tumor necrosis factor
2	Tregs phenotype
2	Treatment targets
2	Toxicity
2	Toulouse
2	Total splenocytes
2	Tocilizumab treatment
2	Tnfa
2	Tissue factor mrna
2	Time points
2	Tetanus
2	Tetanus toxoid
2	Takeda
2	Systemic symptoms
2	Systemic steroids
2	Systemic lupus erythematosus patients
2	Synthetic dmards
2	Synthetic dmard
2	Synovial inflammation
2	Synovial biopsies
2	Symptom duration
2	Supplementary table
2	Supernatant
2	Sulfasalazine
2	Subunit
2	Subluxing arthropathy
2	Study treatment
2	Study design
2	Structural progression
2	Stromal cells
2	Steering committee
2	Statin
2	Spedali civili
2	Special surgery
2	Southern denmark
2	Soluble receptor
2	Small joints
2	Sjogren syndrome
2	Sirna
2	Serum amyloid
2	Sensitivity analysis
2	Sclerosis
2	Rituximab treatment
2	Risk factor
2	Rhumatologie
2	Rheumatology clinic
2	Rheumatic disease
2	Response rate
2	Residual disease activity
2	Remission rate
2	Relapse
2	Regression analysis
2	Regeneron
2	Recommendations table
2	Recombinant
2	Receptor activator
2	Radiological
2	Radiological progression
2	Radiologic damage
2	Radiographic damage
2	Ptga
2	Prosthesis
2	Proc natl acad
2	Printo
2	Primary syndrome
2	Previous treatments
2	Present study
2	Predictor
2	Predictive validity
2	Preclinical phase
2	Positivity
2	Porto alegre
2	Poor prognostic factors
2	Polymyositis
2	Polymorphism
2	Pneumococcal
2	Plasmablast
2	Plasma cells
2	Placebo group
2	Physical activity
2	Phosphatase
2	Pharmaceutical
2	Periodic syndrome
2	Periodic fever
2	Pediatric rheumatology
2	Passive motion
2	Partial response
2	Outcome measures
2	Other indications
2	Original abatacept group
2	Omeract
2	Obesity
2	Nsaid
2	Nordisk
2	Node
2	Nlrp3
2	Nishimoto
2	Necrosis factor
2	Myocardial infarction
2	Multicentric castleman disease
2	Msc
2	Mouse
2	Mouse model
2	Monoclonal
2	Molecular medicine
2	Mitsubishi tanabe pharma
2	Minimal disease activity
2	Mevalonate kinase
2	Metabolic
2	Medical university
2	Mediator
2	Medecine
2	Mavrilimumab
2	Many years
2	Malady
2	Magnetic resonance imaging
2	Lupus erythematosus
2	Lung disease
2	Lower limit
2	Logistic regression
2	Literature review
2	Lipoprotein
2	Lipid levels
2	Lille
2	Li2p
2	Lesser extent
2	Ldas
2	Kingdom background
2	Kinase
2	Joint space
2	Joint involvement
2	Joint destruction
2	January
2	Intravenous
2	Insulin
2	Insulin sensitivity
2	Innate immunity
2	Infusion reactions
2	Infectious diseases
2	Individual patients
2	Incidence rates
2	Inadequate responses
2	Inactive disease
2	Important role
2	Immunosuppressive activity
2	Immunoglobulin
2	Immunization
2	Immune system
2	Immune responses
2	Immune cells
2	Hypertension
2	Humoral
2	Humoral response
2	Humanized
2	Humanized receptor antibody
2	Humanised
2	Humanised receptor
2	Human receptor
2	High doses
2	High disease activity
2	Heterogeneity
2	Healthy donors
2	Healthcare
2	Good response
2	Good responders
2	Gmbh
2	Glucose
2	Glucocorticoid therapy
2	Glostrup
2	Glostrup hospital
2	Giant cell arteritis
2	General population
2	Functional assay
2	Fracture
2	Foxp3
2	Final results
2	Fcgr3a
2	Fcgr3a genotype
2	Favorable outcome
2	Familial
2	Extrathymic
2	Expert committee
2	Erosive arthropathy
2	Epidemiological research table
2	Enthesitis
2	Endothelial cells
2	Elderly patients
2	Eisai
2	Effector
2	Effector cells
2	Early stage
2	Early arthritis
2	Drug Resistance
2	Double-Blind Method
2	Dose escalation

Manipulations en shell (Unix/Dilib)

HfdCat /Users/jacquesducloy/Documents/WicriRoot/Wicri/Sante/explor/Tocilizumab.storage/TocilizumabV1/Data/France/Analysis/Teeft.i.hfd| SxmlCut idx/l | grep ...

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021

	Serveur d'exploration Tocilizumab - Analysis (France) Index « Teeft.i » - tête de navigation
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration Tocilizumab - Analysis (France)Index « Teeft.i » - tête de navigation

Index : Teeft.i

Les termes de plus forte occurence

Manipulations en shell (Unix/Dilib)

Serveur d'exploration Tocilizumab - Analysis (France)

Index « Teeft.i » - tête de navigation